Clinical trials: Cancer, Gastrointestinal
Colorectal Cancer
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
PD-1(programmed death protein 1)antibody has been to approved in patients with MSI-H/dMMR advanced cancer and has achieved significant efficacy.
- Trial name
- PCOX (NCT03638297)
- Testing
- PD-1 antibody + cox inhibitor
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have higher pCR.
- Trial name
- NCT07573397
- Volunteers
- 88 people
- Sponsor
- Fudan University
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors
A first-in-human evaluation of SYN004, a monoclonal antibody that binds to the EGF receptor on cancer cells. Cetuximab, a marketed antibody, has been shown to be effective by inhibiting the growth of cancer cells thereby…
- Trial name
- SYN004_Ph_1 (NCT02391727)
- Testing
- SYN004
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synermore Biologics Co., Ltd.
Esophageal Cancer, Lung Cancer
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens.
- Conditions
- Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer
- Trial name
- NCT00291473
- Testing
- CHP-HER2, CHP-NY-ESO-1
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Lidocaine for Oxaliplatin-induced Neuropathy
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen.
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Trial name
- NCT03254394
- Testing
- Lidocaine Hydrochloride, FOLFOX regimen
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Gastro Intestinal Cancer, Scoring Systems
Comparison of Scoring Systems in Gastrointestinal Cancer Surgery
Accurate prediction of postoperative morbidity and mortality is essential for optimizing perioperative management in patients undergoing gastrointestinal cancer surgery.
- Trial name
- NCT07325656
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Lütfi Kırdar City Hospital
Radiotherapy Induced Mucositis, Head and Neck Cancer
A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer
The primary hypothesis of this study is that regular topical oral application of Manuka Honey will reduce the severity and duration of oral mucositis in patients who are undergoing mucotoxic radiation therapy for cancer treatment.
- Trial name
- NCT00615420
- Testing
- manuka honey
- Where
- 2 sites in Canada
- Volunteers
- 106 people
- Sponsor
- British Columbia Cancer Agency
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Advanced Gastric Cancer
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior…
- Trial name
- NCT00519324
- Testing
- Everolimus
- Where
- 8 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
The goal of this clinical trial is to evaluate the efficacy and safety of camrelizumab plus apatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.
- Trial name
- NCT06546280
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Zhujiang Hospital
Colorectal Neoplasms
TAS-OX for Refractory Metastatic Colon Cancer
This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX…
- Trial name
- NCT02848079
- Testing
- combined TAS-102 and TAS-OX
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
This is an prospective, interventional, non-randomized multicenter phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib as a second-line therapy (after one prior systemic therapy) in patients with…
- Trial name
- CaboCHILD (NCT04454762)
- Testing
- Cabozantinib
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Johannes Gutenberg University Mainz
Overall Survival, Postoperative Complications
Clinical Value of Left Colic Artery in Laparoscopic Radical Rectectomy
Colorectal cancer is one of the most common tumors in Asia. According to the recent research, surgical procedure could provide more treatment benefit in rectal cancer.
- Trial name
- NCT03349788
- Testing
- LCA-nP, LCA-P
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Metastatic Pancreatic Cancer
Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
The purpose of this study is to determine whether molecularly tailored therapy can improve the efficacy of treatment when compared to standard chemotherapy combinations for patients with metastatic pancreatic cancer receiving…
- Trial name
- PanCAN (NCT02967770)
- Testing
- Molecularly Tailored Second Line Therapy, Standard of Care Second Line Therapy
- Where
- United States
- Sponsor
- Georgetown University
Pancreatic Cancer
Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
This is a prospective, single-arm, single-center exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of a triplet regimen-becotatug vedotin combined with anti-PD-1 and S-1-in patients with…
- Trial name
- NCT07892573
- Testing
- Becotatug Vedotin, Anti-PD-1 antibody, S-1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Pancreas Cancer, Pancreatic Ductal Adenocarcinoma
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
- Conditions
- Pancreas Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
- Trial name
- KetoROCX (NCT05336266)
- Testing
- Ketorolac Tromethamine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Andrew Hendifar, MD
Urothelial Bladder Cancer, Gastric Adenocarcinoma
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles…
- Conditions
- Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer
- Trial name
- NIRADO (NCT04779151)
- Testing
- Dostarlimab, Niraparib
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer (Advanced Stage)
Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors
This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer…
- Trial name
- NCT07645742
- Testing
- Alternate-Day Fasting (ADF), Time-Restricted Eating (TRE)
- Volunteers
- 90 people
- Sponsor
- West Virginia University
Breast Cancer, Colon Cancer
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment.
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer
- Trial name
- WWE (NCT01789983)
- Testing
- Walk With Ease Program, Collect Blood, GA and Other Survey Tools
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
This phase I trial studies the best dose of hydroxychloroquine when given together with binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04132505
- Testing
- Binimetinib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.